Ronald Aldridge
Nessuna posizione attualmente
Storia della carriera di Ronald Aldridge
Precedenti posizioni note di Ronald Aldridge
Società | Posizione | Inizio | Fine |
---|---|---|---|
PAREXEL INTERNATIONAL CORPORATION | Contatto Relazioni con gli Investitori | 01/04/2016 | 01/10/2017 |
CONSTELLATION PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | - | - |
THE PHOENIX COMPANIES, INC. | Public Communications Contact | - | - |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Posizioni
Investor Relations Contact | 2 |
Public Communications Contact | 1 |
Settori
Finance | 2 |
Commercial Services | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
The Nassau Cos. of New York, Inc.
The Nassau Cos. of New York, Inc. Life/Health InsuranceFinance The Nassau Cos. of New York, Inc. is a holding company, offers annuities and life insurance services. Its products include life insurance, annuities, product prospectuses and application and forms. The company was founded in 1851 and is headquartered in Hartford, CT. | Finance |
PAREXEL International Corp.
PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Ronald Aldridge
- Esperienza